Annual research progress of systemic therapy for hepatocellular carcinoma in 2024
XUN Chen
QIN Shukui
Abstract：Objective Hepatocellular carcinoma(HCC)is a common malignant tumor in the whole world,and especially has a high incidence in China.In recent years,the 5-year survival rate has been significantly improved,due to the successful systemic therapy researches of advanced HCC.However,there is still a lot of left to be desired.In 2024,multiple results of large phase 3 clinical studies and some potential phase 2 studies have come out,which may have a profound impact on current clinical practice.This article summarized the key clinical research progress of hepatocellular carcinoma in 2024 and provided brief comments with them,hoping to serve reference for clinical workers.
Keywords：Hepatocellular carcinomaClinical studiesAnnual progressAdvanced stagePerioperative period
Publication Date：2025-03-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：11( 276-286 )